Effectiveness of Shared Decision Making(SDM)on Patients With Poor Control Type 2 Diabetes (SDM)
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Background Diabetes and hyperglycemia not only increase the risk of complications of cardiovascular disease and lead to a situation involving exposure to danger of death. Meanwhile, the patient's self-management is one of the key factors affecting the quality control of blood sugar. Thereby, Shared Decision Making (SDM) is a patient-centered medical implementation method that healthcare professionals and patients jointly participate in treatment decision-making to reach a consensus, which can stimulate the health care ability of participants to achieve treatment goals.
Purpose: This research aims to implement the SDM model based on self-efficacy theory through individualized decision-making to strengthen the behavioral motivation of diabetic patients and finally, to improve the patient's health promotion behavior and the effectiveness of blood sugar control.
Method: Study Type: Interventional Actual Enrollment:76 participants Allocation:Randomized Intervention Model:Parallel Assignment Masking:Single(Participant)
Expected results:
It is hoped that the implementation of SDM model will be used to strengthen the behavioral motivation of diabetic patients through individualized decision-making, and to confirm whether it can effectively improve the patient's health behavior and the effectiveness of disease control.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Taiwan
-
Tainan、Taiwan、台湾、709204
- An Nan Hospition-China Medical University
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Aged>20y/o
- Diagnosed by a physician as type 2 diabetes
- The Diabetes Participated in the Diabetes Shared Care Network
- Glycosylated hemoglobin (A1C)> 7.5%
- Can communicate in Chinese or Taiwanese.
Exclusion Criteria:
- People with mental or cognitive impairment who cannot communicate
- Health Literacy score lower than 6 points
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:Control group:as usual care
The control group received as usual care.
|
|
|
実験的:Experimental group:The intervention of SDM
The experimental group received the intervention of SDM 3 times for 3 months,
|
The experimental group received the intervention of SDM 3times/month for 3months, then follow the health promotion behavior compliance by phone once a month.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diabetes self-efficacy scale
時間枠:Pre-test (baseline)
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
Pre-test (baseline)
|
|
Diabetes self-efficacy scale
時間枠:1 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
1 months after intervnetion
|
|
Diabetes self-efficacy scale
時間枠:3 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
3 months after intervnetion
|
|
Diabetes health literacy scale
時間枠:Pre-test (baseline)
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
Pre-test (baseline)
|
|
Diabetes health literacy scale
時間枠:3 months after intervnetion
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
3 months after intervnetion
|
|
Diabetes health promotion scale
時間枠:Pre-test (baseline)
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
Pre-test (baseline)
|
|
Diabetes health promotion scale
時間枠:1 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
1 months after intervnetion
|
|
Diabetes health promotion scale
時間枠:3 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
時間枠:3 months after intervnetion
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months.
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
時間枠:Pre-test (baseline)
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months
|
Pre-test (baseline)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- FooyinU
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。